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orneal collagen cross-linking (CXL) is currently the 
only treatment able to slow or halt the progression 
of ectatic disease.1-4 Long-term follow-up studies 
on CXL refer to the standard technique (S-CXL), which en-
tails epithelial debridement to allow riboflavin (hydrophilic) 
penetration in the corneal stroma; otherwise the corneal epi-
thelium (lipophilic) reduces its permeability.5 Nevertheless, 
epithelial removal causes postoperative pain,6 delayed visual 
recovery,1,7,8 and increased risks of infection. Transepithelial 
cross-linking (TE-CXL) was introduced to avoid these threats. 
The original dextran-containing solutions have been reported 
to be ineffective for TE-CXL,9-11 but other formulations of ri-
boflavin (with chemical enhancers)12 showed equivocal re-
sults in clinical studies.13-15 Conversely, preliminary results 
have shown that transepithelial cross-linking with iontopho-
resis (I-CXL) is able to increase the riboflavin concentration 
inside the stroma compared to other TE-CXL techniques to-
gether with histological changes.16-18 Pilot clinical findings 
using I-CXL with19 and without20 epithelial removal have 
also reported encouraging results. In this study, we compared 
1-year results of two groups of patients with keratoconus who 
CABSTRACT
PURPOSE: To compare 1-year transepithelial corneal 
collagen cross-linking with iontophoresis (I-CXL) out-
comes with standard CXL (S-CXL) epithelium-off for pro-
gressive keratoconus.
METHODS: Forty eyes of 40 patients with progressive 
keratoconus were included in this comparative, pro-
spective clinical study. Corrected distance visual acuity 
(CDVA), spherical equivalent, cylinder refraction, cor-
neal topography, Scheimpflug tomography, aberrometry, 
and endothelial cell count were assessed at baseline 
and at 1, 3, 6, and 12 months of follow-up. 
RESULTS: Patients received either I-CXL (20 eyes) or 
S-CXL (20 eyes). Functional parameters (visual acuity 
and aberrometry) showed a significant improvement (P 
< .05) after 6 and 12 months of follow-up in both 
groups. In the I-CXL group, the CDVA showed a rapid 
recovery of vision after 3 months (P = .01) compared 
to baseline. Morphological parameters showed a signif-
icant reduction of maximum keratometry in the S-CXL 
group by -1.05 ± 1.51 diopters (D) after 12 months, 
whereas the I-CXL group curvature was stable (-0.31 
± 1.87 D). Minimum pachymetry values were stable 
even after 12 months of follow-up in the I-CXL group, 
whereas a significant corneal thinning 12 months fol-
lowing treatment was recorded in the S-CXL group (P 
< .001). None of the patients had continuous progres-
sion of keratoconus or had to repeat CXL procedures. 
Endothelial cell counts did not change significantly (P 
> .05).
CONCLUSIONS: The 1-year outcomes suggest that 
I-CXL might be comparable to S-CXL in stabilizing the 
progression of the degenerative ectatic disease. Addi-
tionally, quicker improvement of functional parameters 
was reported in the I-CXL group. 
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were treated with I-CXL and S-CXL (epithelium-off 
Dresden protocol).
PATIENTS AND METHODS
In this comparative, prospective, non-randomized, 
single-center interventional study, we included 40 
eyes of 40 patients who underwent I-CXL or S-CXL 
at the Eye Center, Humanitas Clinical and Research 
Center (Rozzano, Milan, Italy). The inclusion criteria 
for the treatment of CXL were documentation of the 
progression of keratoconus and patients older than 9 
years.7 Exclusion criteria were a history of herpetic 
keratitis, dry eye, severe corneal infection, concomi-
tant ocular or systemic autoimmune disease, diag-
nosed pregnancy or breastfeeding, the presence of cen-
tral or paracentral opacities, low compliance, and the 
use of rigid contact lenses for more than 4 weeks before 
the baseline evaluation.
The study received Institutional Review Board ap-
proval from the ethical committee of the Humanitas Clin-
ical and Research Center and was conducted according 
to the tenets of the Declaration of Helsinki, as revised in 
2000. All patients provided informed consent.
The following parameters were assessed in the pre-
operative and postoperative course (1, 3, 6, and 12 
months): corrected distance visual acuity (CDVA), slit-
lamp biomicroscopy, Goldmann tonometry, dilated 
funduscopy, corneal topography, and anterior corneal 
aberrometry for the evaluation of low and higher order 
aberrations (HOAs) (Costruzione Strumenti Oftalmici, 
Florence, Italy), optical tomography (Cirrus HD-OCT; 
Carl Zeiss Meditec, Dublin, CA), pachymetry with Pen-
tacam (Oculus Optikgeräte, GmbH, Wetzlar, Germany), 
and endothelial biomicroscopy (Konan Specular Mi-
croscope; Konan Medical, Inc., Hyogo, Japan) before 
and 1 month after surgery.
The documentation of the progression and all pre-
operative and postoperative functional and morpho-
logical tests were performed in an identical manner to 
a previously published clinical study,20 and postopera-
tive complications were recorded. 
The iontophoresis protocol entails the use of ri-
boflavin solution specifically designed for the pro-
cedure, consisting of 0.1% riboflavin, no dextran or 
sodium chloride with the addition of two enhanc-
ers: ethylenediaminetetraacetic acid (EDTA) and tro-
metamol (Ricrolin; Sooft, Montegiorgio, Italy). The 
corneal iontophoresis electrode was filled with ap-
proximately 0.5 mL of riboflavin solution from the 
open proximal side, until the electrode (stainless steel 
mesh) was covered. The device was then connected to 
a constant current generator (I-ON XL; Sooft) set at 1 
mA (the total dose of 5 mA/5 minutes is monitored by 
the generator). Subsequently, the cornea was irradi-
ated at a working distance of 45 mm with an ultravio-
let lamp of 10 mW (UV-X 2000; IROC Innocross AG, 
Zurich, Switzerland) for 9 minutes.20 Conversely, the 
standard protocol, which we previously described in 
other publications,7 entails a 9-mm epithelial remov-
al with an Amoils brush (Amoils Brush Epithelial 
Scrubber; Vision Technology Co., Seoul, Korea). A so-
lution of riboflavin 0.1% and dextran 20% (Ricrolin; 
Sooft) was then instilled every minute for 30 minutes 
to fully irrigate the cornea. During irrigation, corneal 
thickness was tested using an ultrasound pachymeter 
(SP-2000; Tomey, Erlangen, Germany) to avoid ex-
posing corneas to ultraviolet light when pachymetry 
was less than 400 µm. When required, a hypo-osmo-
lar 0.1% riboflavin solution was instilled to promote 
corneal swelling. The last phase of the procedure in-
cludes ultraviolet-A irradiation, where a 7.5-mm di-
ameter of the central cornea is treated with an irradi-
ance of 3 mW/cm2 (UV-X System; Peschke Meditrade 
GmbH, Huenenberg, Switzerland) for 30 minutes. 
A soft therapeutic contact lens was applied in both 
groups, even if corneal epithelium was not removed in 
the I-CXL group, because the high intensity of ultravio-
let light can damage the epithelium for the first days 
after the procedure. Postoperatively, an ophthalmic 
gel containing 0.15% sodium hyaluronate, 1% xan-
than gum, and 0.3% netilmicin (Xanternet; SIFI SpA, 
Catania, Italy) was prescribed four times daily until no 
epithelium damage was seen (epithelial integrity was 
evaluated with fluorescein staining daily postopera-
tively) and, after removal of contact lens, dexameth-
asone 21-phosphate 0.15% drops (Etacortilen; Sifi, 
Lavinaio, Italy) were prescribed two times daily for 10 
days and 0.15% sodium hyaluronate drops (BluYal; 
Sooft) were prescribed six times daily for 45 days. In 
addition, all patients received oral amino acid supple-
ments (Aminoftal; Sooft) for 7 days.21
StatiStical analySiS
Statistical analysis was performed using the SPSS 
statistical software (version 20.0; IBM Corp., Armonk, 
NY). Data are described as mean ± standard deviation. 
The Shapiro–Wilks W test was performed to confirm 
the normality distribution of the data prior to analy-
sis. The Student’s t test for paired data was applied to 
assess the significance of differences between preop-
erative and postoperative data and an unpaired two-
sided Student’s t test was used to compare continuous 
variables. A linear regression analysis was performed 
for maximum keratometry (Kmax), CDVA, coma, and 
HOAs. A P value of less than .05 was considered sig-
nificant in all cases.
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RESULTS
Forty eyes of 40 patients were prospectively evalu-
ated, 20 in each group (I-CXL and S-CXL). The mean 
age was 28.2 ± 8.5 years in the S-CXL group and 27.8 
± 6.4 years in the I-CXL group (the difference was not 
significant, P = .86). All patients had 1, 3, 6, and 12 
months of follow-up, except in the I-CXL group where 
1 patient was lost to follow-up at month 3 and 3 pa-
tients at month 12. Clinical features of the patients 
and their preoperative and follow-up data are listed in 
Table A and Table B (available in the online version of 
the article), respectively.
Comparison at baseline demonstrated no significant 
difference in the biometric parameters, in particular 
the preoperative Kmax (P = .10), minimum pachym-
etry (P = .67), and progression rate (1.52 ± 0.70 D in 
the S-CXL group and 1.52 ± 0.20 D in the I-CXL group) 
(P = .98). Table 1 shows the comparison between the 
groups.
Functional analySiS
Visual Acuity. The statistical analysis showed a sig-
nificant increase in CDVA compared to baseline in both 
groups (P < .05). However, the I-CXL group already 
showed a significant increase in CDVA compared to 
baseline at the 3-month follow-up, whereas the S-CXL 
group improved significantly after 6 months. Linear 
regression analysis was significant in both groups, al-
though it was stronger in the I-CXL group (I-CXL: P = 
.0002, R = 0.98; S-CXL: P = .013, R = 0.6), showing a 
quicker improvement in the I-CXL group compared to 
the S-CXL group (Figure 1).
Refractive Results. Spherical refraction showed a 
significant reduction (P < .05) at all postoperative fol-
low-up times in the I-CXL group. Conversely, it was 
stable after S-CXL (P > .05). The results for cylinder 
variation after S-CXL presented a significant increase 
at months 1 and 3 compared to baseline, followed by 
a return to a nonsignificant improvement at the oth-
er follow-up times. Cylinder refraction also did not 
change significantly after I-CXL.
Aberrometric Results. Aberrometric results showed 
a significant worsening of HOAs, coma, and spherical 
aberration at month 1 (P < .05). Subsequently, coma 
and HOAs improved significantly, compared to base-
line, after 6 and 12 months of follow-up in the I-CXL 
TABLE 1
Comparison of S-CXL and I-CXL
Difference With Baseline at 12 Months
Outcomes S-CXL I-CXL P
CDVA (logMAR) -0.05 ± 0.11 -0.10 ± 0.10 .20
Sphere (D) 0.47 ± 1.15 0.90 ± 1.54 .30
Cylinder (D) -0.43 ± 1.47 0.20 ± 1.39 .20
Kmax (D) -1.05 ± 1.51 -0.31 ± 1.87 .008
SAI -0.88 ± 1.50 -0.55 ± 1.52 .30
SI -0.25 ± 1.48 1.06 ± 1.92 .50
ISV -6.20 ± 11.28 0.60 ± 7.90 .04
IVA -0.05 ± 0.19 -0.02 ± 0.12 .20
KI -0.03 ± 0.04 0.08 ± 0.02 .0002
CKI -0.02 ± 0.03 0.01 ± 0.02 .08
IHA 0.07 ± 28.4 -6.80 ± 16.98 .90
IHD -0.01 ± 0.02 0.04 ± 0.14 .60
Rmin 0.21 ± 0.20 -0.06 ± 0.25 .0001
ThCT (µm) -41.10 ± 35.30 1.00 ± 7.20 < .001
HOA -0.03 ± 0.18 -0.33 ± 0.78 .01
Coma -0.19 ± 0.31 -1.16 ± 1.64 .01
Ab sph -0.02 ± 0.10 0.09 ± 0.56 < .001
S-CXL = standard corneal collagen cross-linking; I-CXL = transepithelial cornal collagen cross-linking with iontophoresis; CDVA = corrected distance visual acu-
ity; sphere= spherical refraction; D = diopters; Kmax = maximum keratometry; SAI = surface asymmetry index; SI = symmetry index; ISV = index of surface 
variance; IVA = index of vertical asymmetry; KI = keratoconus index; CKI = central keratoconus index; IHA = index of height asymmetry; IHD = index of height 
decentration; Rmin = minimum radius of curvature; ThCT = minimum pachymetry; HOA = higher order aberrations; coma = comatic aberration; Ab sph = spheri-
cal aberration
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Figure 1. Linear regression analysis of corrected distance visual acuity 
expressed as logMAR (CDVA) in the corneal collagen cross-linking with 
iontophoresis (I-CXL) and standard CXL (S-CXL) groups.
Figure 2. Linear regression analysis of comatic aberration in the corneal 
collagen cross-linking with iontophoresis (I-CXL) and standard CXL (S-CXL) 
groups. 
Figure 3. Linear regression analysis of higher order aberrations (HOAs) in 
the corneal collagen cross-linking with iontophoresis (I-CXL) and standard 
CXL (S-CXL) groups. 
group, whereas the S-CXL group showed an improve-
ment only in coma after 6 and 12 months. However, 
regression analysis of coma (P = .0001, R = 0.15) and 
HOAs (P = .001, R = 0.20) was significant in the I-CXL 
group (Figure 2) but not in the S-CXL group (coma: P 
= .49, R = 0.005; HOAs: P = .021, R = 0.15) (Figure 3). 
Comparative analysis of the improvement induced 
by I-CXL compared to S-CXL regarding HOA and coma 
aberrations (Table 1) showed a significant difference 
between the groups: a reduction of -1.16 ± 1.64 µm for 
coma and -0.33 ± 0.78 µm for HOAs in the I-CXL group 
and -0.19 ± 0.31 µm for coma and -0.03 ± 0.18 µm for 
HOAs in the S-CXL group (P = .01).
Structural analySiS
Topographic Results. Topographic results for I-CXL 
and S-CXL are shown in Tables A-B. The morphologi-
cal indices indicate a stabilization of keratoconus in both 
groups. The analysis of the topographic results showed 
a significant worsening of numerous topographic indices 
and Kmax in either the S-CXL or I-CXL group at month 
1. However, I-CXL did not cause a worsening of index 
of vertical asymmetry and index of height decentration, 
whereas S-CXL did. After this initial worsening, S-CXL 
induced a significant improvement of numerous topo-
graphic indices during the follow-up (Table B). In partic-
ular, Kmax was reduced significantly by -1.05 ± 1.51 D af-
ter 12 months (P < .01). Conversely, I-CXL only showed a 
significant improvement of corneal symmetry index after 
12 months of follow-up. The reduction of -0.31 ± 1.87 of 
Kmax did not reach statistical significance (P = .20). Com-
parative analysis showed a significant difference in the 
induced flattening between S-CXL and I-CXL (P < .01), 
with S-CXL performing better. However, linear regression 
Figure 4. Linear regression analysis of maximum keratometry (Kmax) in 
the corneal collagen cross-linking with iontophoresis (I-CXL) and standard 
CXL (S-CXL) groups.
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analysis was not significant in either group (I-CXL: P = 
.27, R = 0.13; S-CXL: P = .28, R = 0.12) (Figure 4).
Pachymetry Results. Pachymetry results for I-CXL 
and S-CXL are summarized in Tables A-B. The main 
result of this analysis is that there is a statistically sig-
nificant thinning of the minimum corneal thickness in 
the S-CXL group (P = .0001), whereas this did not oc-
cur after I-CXL. Comparative analysis confirmed this 
result, showing an increase of minimum pachymetry 
of 1.0 ± 7.2 µm after 12 months in the I-CXL group, 
whereas the S-CXL group showed a decrease of 
pachymetry of -41.1 ± 35.3 µm compared to baseline, 
even after 12 months of follow-up; this difference was 
statistically significant (P < .001).
As reported in a previous article,20 no clear demar-
cation line was measurable with anterior segment opti-
cal coherence tomography, but an increase of anterior 
stroma reflectance was noted after I-CXL. After S-CXL, 
the demarcation line was clear and visible at the stan-
dard depth of an epithelium-off procedure. 
All of the patients who underwent I-CXL revealed 
a punctate keratitis the first postoperative day. The 
contact lens was removed on the second day, except 
in 1 patient who showed a central erosion of the epi-
thelium that healed in 2 days. Conversely, the con-
tact lens in the S-CXL group was removed between 
3 and 5 days postoperatively, when the cornea was 
reepithelialized. 
None of the patients developed infection or haze, 
and no other complications occurred.
DISCUSSION
Due to the known limitations of CXL with epithelial 
removal, a CXL procedure that spares the epithelium 
while retaining maximal efficacy is highly desirable. To 
our knowledge, this is the first comparative prospective 
clinical study in which preoperative and postoperative 
refractive, topographic, tomographic, and aberrometric 
outcomes have been analyzed in eyes with progressive 
keratoconus treated with a commercial ocular ionto-
phoresis device or standard Dresden protocol CXL.
In general, it is known that S-CXL with epithelial re-
moval reduces or halts the progression of keratoconus, 
inducing significant improvements in morphological 
and functional parameters as shown in the S-CXL group 
and in previous reports,1,7 but the efficacy of I-CXL is 
unclear. Our results support the concept that I-CXL may 
be effective in halting the progression of keratoconus. 
First, our study shows that I-CXL treatment stimu-
lates a higher and quicker improvement of visual acu-
ity compared to S-CXL. Given the stability induced by 
both protocols, this faster return to baseline CDVA is 
an important advantage of I-CXL.
Additionally, I-CXL promoted a greater reduction of 
HOAs and coma and it did not cause a decrease in mini-
mum pachymetry. This last finding is relevant because 
it has been reported that a permanent stromal scar tends 
to develop in patients with thin corneas after S-CXL.2,7 
No patients developed deep stromal opacities after I-
CXL, even those who had a preoperative minimum cor-
neal thickness less than 400 µm. Moreover, minimum 
corneal thickness values were stable at up to 12 months 
of follow-up after I-CXL. There was a slight thinning of 
this value in the S-CXL group. Nevertheless, it is known 
that pachymetry values tend to increase after 12 to 24 
months of follow-up with S-CXL.7 
The I-CXL group showed a significant decrease in 
sphere values, whereas the S-CXL group was stable at 
12 months of follow-up. Conversely, S-CXL induced 
a higher flattening effect together with a significant 
reduction of various topographic indexes. More long-
term comparative studies will be needed to evaluate if 
the comparative outcomes of S-CXL and I-CXL will be 
different after 12 months of follow-up.
Anterior segment optical coherence tomography 
after I-CXL shows a completely different image com-
pared to that after S-CXL. In S-CXL, an increase of 
reflectance with a white line (demarcation line) is 
normally visible.22 In I-CXL, it is possible to detect 
a similar increase of reflectance, but no white line is 
visible. This finding could be explained by either the 
different concentration gradient induced by I-CXL or a 
reduced CXL effect.
These results highlight the clinical efficacy of I-CXL 
to overcome the problems of TE-CXL: the penetration 
of riboflavin through the epithelium. It is known that 
the corneal epithelium and Bowman’s layer mostly 
absorb ultraviolet-B light (up to 300 nm) but they al-
low penetration of ultraviolet-A light.23 Bottós et al. 
showed that the reduced effect of TE-CXL compared to 
S-CXL is principally due to the limited penetration of 
riboflavin through the epithelium, and confirmed that 
it is not a barrier to ultraviolet-A transmittance.24  
However, it is known from preclinical reports that 
the biomechanical effect, riboflavin penetration, and 
distribution of I-CXL are higher than in TE-CXL but 
lower when compared to S-CXL.17,18,25 This compara-
tive clinical study will continue the follow-up of the 
patients to determine whether this stiffening effect, 
even if reduced, will be enough to halt the ectatic dis-
ease in the long term.
As previously reported,20 our findings are in partial 
agreement with the 1-year follow-up report by Bikbova 
and Bikbov26 of 9 patients treated with I-CXL. Their re-
sults showed that I-CXL is able to halt the progression 
of keratoconus, but they did not report any significant 
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change in functional parameters, only a significant de-
crease in corneal thickness after 6 months of follow-
up. We previously described the differences between 
the two studies and the limitations of the considered 
report.20
Our findings are in agreement with a preliminary, 
unpublished, 6-month follow-up report of a random-
ized, controlled, prospective comparative clinical 
study of I-CXL versus S-CXL that showed comparable 
results of the two protocols.27 However, in this study, 
the I-CXL procedure was modified using a Biopore 
membrane to remove the mucin layer. 
The principal limits of our study are the relatively 
small number of patients and the 1-year follow-up, 
which might be not sufficient to judge the safety and 
efficacy of this transepithelial approach. The energy 
dose used may be a further limitation. The total energy 
dose of 5.4 J/cm2 was applied to be comparable to all 
other historical published S-CXL1,2 and TE-CXL28 stud-
ies that chose this dose. However, Zhang et al. showed 
that the epithelial cells are not enriched with ribofla-
vin.28 For that reason, only part of the ultraviolet light 
should be absorbed by the epithelium, approximately 
15% to 20%.29 Therefore, it could be advisable to in-
crease the energy dose in I-CXL by 20% to 6.5 J/cm2. 
This comparative prospective clinical study demon-
strated that I-CXL has the potential to become a valid 
alternative to halt the progression of keratoconus while 
reducing patients’ postoperative pain, risk of infection, 
and treatment time.
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TABLE A 
Transepithelial Corneal Collagen Cross-linking With Iontophoresis Data
Outcomes Baseline 1 Month P 3 Months P 6 Months P 12 Months P
CDVA  
(logMAR)
0.25 ± 0.15 0.25 ± 0.22 .13 0.20 ± 0.18 .01 0.12 ± 0.13 .0004 0.12 ± 0.15 .0003
Sphere (D) -2.03 ± 2.89 -1.42 ± 2.42 .06 -1.31 ± 2.72 .003 -1.13 ± 3.06 .001 -1.14 ± 2.72 .02
Cylinder (D) -3.16 ± 1.31 -3.18 ± 1.21 .86 -3.28 ± 1.31 .55 -3.40 ± 1.44 .27 -3.03 ± 1.47 .56
Kmax (D) 59.07 ± 3.90 59.63 ± 3.44 .05 59.45 ± 3.71 .96 58.69 ± 3.45 .35 58.22 ± 3.90 .44
SAI 7.79 ± 3.86 8.27 ± 3.82 .01 7.65 ± 3.76 .70 7.51 ± 3.81 .55 6.65 ± 3.55 .15
SI 8.98 ± 5.06 9.53 ± 5.21 .07 9.62 ± 4.96 .18 9.82 ± 5.23 .08 8.97 ± 4.64 .04
ECD (µm) 2,446 ± 209.7 2,508 ± 226.12 .40 – – – – – –
ISV 106.68 ± 31.51 109.2 ± 31.34 .0013 105.68 ± 32.52 .50 107.72 ± 33.35 .69 97.56 ± 29.01 .77
IVA 1.20 ± 0.44 1.19 ± 0.43 .20 1.16 ± 0.45 .78 1.19 ± 0.46 .73 1.04 ± 0.38 .47
KI 1.29 ±0.11 8.03 ± 30.12 .30 1.28 ± 0.10 .77 1.30 ± 0.12 .34 1.26 ± 0.10 .24
CKI 1.06 ± 0.04 1.08 ± 0.03 .0025 1.07 ± 0.03 .02 1.07 ± 0.03 .04 1.07 ± 0.03 .05
IHA 31.65 ± 22.55 30.51 ± 26.49 .88 28.64 ± 24.04 .76 26.93 ± 18.79 .57 20.35 ± 14.39 .14
IHD 0.11 ± 0.04 0.11 ± 0.04 .40 0.13 ± 0.11 .37 0.11 ± 0.04 .54 0.13 ± 0.15 .30
Rmin 5.88 ± 0.49 5.81 ± 0.45 .15 5.84 ± 0.48 .22 5.93 ± 0.54 .61 5.91 ± 0.46 .34
ThCT (µm) 434.31 ± 37.84 436.1 ± 38.37 .60 440.73 ± 38.59 .44 444.1 ± 37.23 .30 443.1 ± 36.37 .67
HOA 1.04 ± 0.39 1.12 ± 0.43 .01 0.99 ± 0.42 .45 0.74 ± 0.50 .007 0.62 ± 0.53 .0026
Coma 2.40 ± 1.03 2.56 ± 0.96 .0006 2.42 ± 0.96 .59 1.65 ± 1.14 .006 1.27 ± 0.86 .003
Ab sph 0.14 ± 0.44 0.386 ± 0.49 .03 0.13 ± 0.76 .48 0.29 ± 0.39 .12 0.26 ± 0.42 .77
CDVA = corrected distance visual acuity; sphere= spherical refraction; D = diopters; Kmax = maximum keratometry; SAI = surface asymmetry index; SI = sym-
metry index; ECD = endothelial cell density; ISV = index of surface variance; IVA = index of vertical asymmetry; KI = keratoconus index; CKI = central kerato-
conus index; IHA = index of height asymmetry; IHD = index of height decentration; Rmin = minimum radius of curvature; ThCT = minimum pachymetry; HOA = 
higher order aberrations; coma = comatic aberration; Ab sph = spherical aberration 
Bold values indicate statistical significance.
TABLE B 
Standard Corneal Collagen Cross-linking Data
Outcomes Baseline 1 Month P 3 Months P 6 Months P 12 Months P
CDVA  
(logMAR)
0.16 ± 0.08 0.15 ± 0.08 .70 0.12 ± 0.08 .10 0.10 ± 0.08 .04 0.10 ± 0.08 .03
Sphere (D) -0.85 ± 2.16 -0.97 ± 2.23 .60 -0.55 ± 2.14 .10 -0.36 ± 2.26 .10 -0.37 ± 2.07 .08
Cylinder (D) -2.52 ± 1.65 -3.21 ± 1.75 .01 -3.28 ± 1.57 .01 -3.03 ± 1.25 .10 -2.96 ± 1.21 .20
Kmax (D) 56.87 ± 4.52 57.36 ± 4.63 .30 56.5 ± 4.35 .40 56.11 ± 4.61 .05 55.82 ± 4.29 .005
SAI 6.03 ± 3.29 6.95 ± 3.36 .0007 6.31 ± 3.05 .20 9.57 ± 19.29 .30 5.15 ± 3.00 .01
SI 7.29 ± 3.83 7.96 ± 3.84 .02 7.56 ± 3.68 .20 7.21 ± 4.05 .70 7.04 ± 3.85 .40
ECD (µm) 2,526 ± 385.5 2,200 ± 122.7 .40 – – – – – –
ISV 79.65 ± 29.39 91.6 ± 27.3 .001 83.9 ± 29.3 .10 76.95 ± 31.22 .20 73.45 ± 28.52 .02
IVA 0.92 ± 0.44 1.08 ± 0.37 .003 1.00 ± 0.39 .60 0.91 ± 0.44 .90 0.86 ± 0.40 .20
KI 1.21 ± 0.09 1.24 ± 0.10 .07 1.21 ± 0.09 .50 1.19 ± 0.11 .04 1.18 ± 0.10 .001
CKI 1.08 ± 0.03 1.05 ± 0.05 .001 1.05 ± 0.06 .10 1.02 ± 0.04 .004 1.01 ± 0.05 .006
IHA 20.88 ± 19.43 26.58 ± 23.32 .30 19.37 ± 15.27 .60 19.32 ± 14.94 .60 20.95 ± 22.20 .90
IHD 0.08 ± 0.04 0.09 ± 0.04 .02 0.13 ± 0.23 .30 0.07 ± 0.04 .10 0.07 ± 0.04 .01
Rmin 6.31 ± 0.58 6.20 ± 0.57 .01 6.35 ± 0.60 .30 6.49 ± 0.64 .0008 6.53 ± 0.62 .0001
ThCT (µm) 472.65 ± 32.86 437.3 ± 36.99 .0001 425.95± 35.64 .0001 429.3 ± 42.08 .0001 431.5 ± 49.9 .0001
HOA 0.83 ± 0.28 0.93 ± 0.31 .01 0.81 ± 0.34 .70 0.83 ± 0.25 .90 0.80 ± 0.26 .40
Coma 1.84 ± 0.82 2.09 ± 0.83 .002 1.87 ± 0.81 .60 1.71 ± 0.83 .02 1.65 ± 0.83 .01
Ab sph 0.003 ± 0.33 0.087 ± 0.37 .01 0.02 ± 0.34 .30 0.008 ± 0.34 .80 0.26 ± 0.42 .20
CDVA = corrected distance visual acuity; sphere= spherical refraction; D = diopters; Kmax = maximum keratometry; SAI = surface asymmetry index; SI = sym-
metry index; ECD = endothelial cell density; ISV = index of surface variance; IVA = index of vertical asymmetry; KI = keratoconus index; CKI = central kerato-
conus index; IHA = index of height asymmetry; IHD = index of height decentration; Rmin = minimum radius of curvature; ThCT = minimum pachymetry; HOA = 
higher order aberrations; coma = comatic aberration; Ab sph = spherical aberration 
Bold values indicate statistical significance.
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